Trial · NCT03573401
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite Clinical and Histological Response of the Subject's Main Target Lesion as Assessed 12 Weeks After the Start of the Last PDT Cycle That Included Treatment of the Main Target Lesion. | 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion | Each subject had one Main Target Lesion. The composite clinical and histological response rate of the subjects' Main Target Lesions is the percentage of subjects with a clinically and histologically cleared Main Target lesion 12 weeks after the start of the last PDT cycle that included treatment of the Main Target Lesion (Visit 5 or Visit 8). |
| Secondary | Main Target Lesion Clinical Response Rate (According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle | 12 weeks after the start of the last PDT cycle | 1\. Key secondary endpoint: Percentage of Main Target Lesions with complete clinical clearance (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle. |
| Secondary | Main Target Lesion Histological Response Rate (According to Histological Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle | 12 weeks after the start of the last PDT cycle | 2\. Key secondary endpoint: Percentage of Main Target Lesions with complete histological clearance (i.e. according to histological assessment only) 12 weeks after the start of the last PDT cycle. |
| Secondary | Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After the Start of the Last PDT Cycle. | 12 weeks after the start of the last PDT cycle | 3\. Key secondary endpoint: Percentage of subjects with complete clinical clearance of all Target Lesions (i.e. according to clinical assessment only) 12 weeks after the start of the last PDT cycle. |
| Secondary | Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After the Start of the Last PDT Cycle. | 12 weeks after the start of the last PDT cycle | 4\. Key secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of all Additional Target Lesions 12 weeks after the start of the last PDT cycle |
| Secondary | Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After the Start of the Last PDT Cycle. | 12 weeks after the start of the last PDT cycle | Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after the start of the last PDT cycle. |
| Secondary | Main Target Lesion Complete Response (Clinically and Histologically Cleared) Assessed 12 Weeks After PDT-1. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of Main Target Lesions that are clinically and histologically cleared 12 weeks after PDT-1. |
| Secondary | Main Target Lesion Clinical Response (According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of Main Target Lesions that are clinically cleared 12 weeks after PDT-1. |
| Secondary | Main Target Lesion Histological Response (According to Histological Assessment Only) Assessed 12 Weeks After PDT-1. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of Main Target Lesions that are histologically cleared 12 weeks after PDT-1. |
| Secondary | Lesion Complete Clinical Response Rate Per Treatment Arm (Complete Clearance of Individual Lesions (Main and Additional Target Lesions)) According to Clinical Assessment Only, Assessed 12 Weeks After PDT-1. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of Individual Target Lesions that are completely clinically cleared per treatment arm 12 weeks after PDT-1 |
| Secondary | Subject Complete Clinical Response (Complete Clearance of All Target Lesions According to Clinical Assessment Only) Assessed 12 Weeks After PDT-1. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of subjects with complete clinical clearance 12 weeks after PDT-1. |
| Secondary | Subject Complete Response (Clinically and Histologically Cleared Main Target Lesion (See Above) and Complete Clinical Remission of All Additional Target Lesions) Assessed 12 Weeks After PDT-1.. | 12 weeks after PDT-1 | Further secondary endpoint: Percentage of subjects with complete clinical and histological clearance of the Main Target Lesion and complete clinical clearance of Additional Target Lesions 12 weeks after PDT-1. |
| Secondary | For All Target Lesions, Assessment of Esthetic Appearance by the Investigator 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion and Any Alternative Treatment of Additional Target Lesions. | 12 weeks after the start of the last PDT cycle | Further secondary endpoint: Investigators assessment of the esthetic appearance of all Target lesions but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions |
| Secondary | Subjects' Satisfaction Regarding Esthetic Outcome and Treatment 12 Weeks After the Start of the Last PDT Cycle, But Prior to Surgical Excision of the Main Target Lesion or Alternative Treatment of Additional Target Lesions | 12 weeks after the start of the last PDT cycle | Further secondary endpoint: Subject's assessment regarding the esthetic outcome and the Treatment 12 weeeks after the start of the last PDT cycle but prior to surgical excision of the Main Target Lesion or alternative Treatment of Additional Target Lesions |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03573401/registered